In accordance with the guidelines from the Moroccan SMR for the therapeutic management of SpA [24], biological treatments are recommended for nr-axSpA patients with an inadequate response to non-steroidal anti-inflammatory drugs, along with specific criteria including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4 or Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥2.1 and positive CRP and/or inflammatory signs on MRI. This evidence concerns the gene CRP and ankylosing spondylitis.